TY - JOUR
T1 - Is antidyslipidemic statin use for cancer prevention a promising drug repositioning approach?
AU - Kobayashi, Yusuke
AU - Banno, Kouji
AU - Kunitomi, Haruko
AU - Nagai, Shimpei
AU - Takahashi, Takayuki
AU - Anko, Mayuka
AU - Iijima, Moito
AU - Takeda, Takashi
AU - Matoba, Yusuke
AU - Nakamura, Kanako
AU - Tsuji, Kosuke
AU - Tominaga, Eiichirou
AU - Aoki, Daisuke
N1 - Funding Information:
This work was supported by KAKENHI (Japan Society for the Promotion of Science, Grant-in-aid; 18K16780).
Publisher Copyright:
Copyright © 2018 Wolters Kluwer Health, Inc. All rights reserved.
PY - 2019/11/1
Y1 - 2019/11/1
N2 - Novel pharmacological therapies are in development for cancer, ranging from conventional chemotherapeutic drugs to molecular targeted drugs, antibody-based drugs, and immune checkpoint inhibitors, which are developed using new technologies. However, the increasing cost of new drug development is increasing the costs of national healthcare and putting pressure on government finances worldwide. Under these circumstances, drug repositioning (i.e. discovering novel effects of existing drugs, thereby allowing their use to treat other diseases) has become a major focus because of reliability and cost reduction. It is becoming increasingly clear that statins (currently used for treating dyslipidemia) can be effective in the prevention of coronary disease, heart failure, and arrhythmia. Epidemiological as well as basic research studies and epidemiological surveys have showed that statins have a suppressive effect on cancers and that they have an antitumor effect on colorectal, prostate, breast, cervical, endometrial, and ovarian cancers. Given the pharmacological mechanism of action of statins, they may have an antitumor effect on cancer types in which the mevalonate pathway is activated as well as on tumors with p53 mutations. To investigate this further, it would be necessary to conduct a large-scale survey after confirming the clinical background of patients as well as their mutational status, and therefore, great hope has been placed on the role of academia and public institutions. Thus, there is an urgent need for researchers to be actively involved in investigator-initiated clinical trials.
AB - Novel pharmacological therapies are in development for cancer, ranging from conventional chemotherapeutic drugs to molecular targeted drugs, antibody-based drugs, and immune checkpoint inhibitors, which are developed using new technologies. However, the increasing cost of new drug development is increasing the costs of national healthcare and putting pressure on government finances worldwide. Under these circumstances, drug repositioning (i.e. discovering novel effects of existing drugs, thereby allowing their use to treat other diseases) has become a major focus because of reliability and cost reduction. It is becoming increasingly clear that statins (currently used for treating dyslipidemia) can be effective in the prevention of coronary disease, heart failure, and arrhythmia. Epidemiological as well as basic research studies and epidemiological surveys have showed that statins have a suppressive effect on cancers and that they have an antitumor effect on colorectal, prostate, breast, cervical, endometrial, and ovarian cancers. Given the pharmacological mechanism of action of statins, they may have an antitumor effect on cancer types in which the mevalonate pathway is activated as well as on tumors with p53 mutations. To investigate this further, it would be necessary to conduct a large-scale survey after confirming the clinical background of patients as well as their mutational status, and therefore, great hope has been placed on the role of academia and public institutions. Thus, there is an urgent need for researchers to be actively involved in investigator-initiated clinical trials.
KW - drug repositioning
KW - mevalonate pathway
KW - statins
UR - http://www.scopus.com/inward/record.url?scp=85063401959&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85063401959&partnerID=8YFLogxK
U2 - 10.1097/CEJ.0000000000000497
DO - 10.1097/CEJ.0000000000000497
M3 - Review article
C2 - 30418231
AN - SCOPUS:85063401959
SN - 0959-8278
VL - 28
SP - 562
EP - 567
JO - European Journal of Cancer Prevention
JF - European Journal of Cancer Prevention
IS - 6
ER -